Cargando…

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment

BACKGROUND: Patients with renal impairment receiving classical anticoagulation for venous thromboembolism (VTE) are at increased risk of bleeding and possibly pulmonary embolism. We examined the efficacy and safety of oral rivaroxaban in patients with VTE with and without renal impairment. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bauersachs, Rupert M, Lensing, Anthonie WA, Prins, Martin H, Kubitza, Dagmar, Pap, Ákos F, Decousus, Hervé, Beyer-Westendorf, Jan, Prandoni, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Original Basic Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351845/ https://www.ncbi.nlm.nih.gov/pubmed/25750589 http://dx.doi.org/10.1186/1477-9560-12-25

Ejemplares similares

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
por: Boonyawat, Kochawan, et al.
Publicado: (2021)

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
por: Prins, Martin H, et al.
Publicado: (2013)

Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

Use of Prestudy Heparin Did Not Influence the Efficacy and Safety of Rivaroxaban in Patients Treated for Symptomatic Venous Thromboem‐bolism in the EINSTEIN DVT and EINSTEIN PE Studies
por: Prandoni, Paolo, et al.
Publicado: (2015)

Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy
por: Wells, Philip S, et al.
Publicado: (2014)

Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study
por: Lensing, Anthonie W. A., et al.
Publicado: (2018)

Anticoagulation in pediatric cancer–associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr
por: Palumbo, Joseph S., et al.
Publicado: (2022)

Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism
por: Prins, Martin H, et al.
Publicado: (2013)

Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban‐treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding
por: Kline, Jeffrey A., et al.
Publicado: (2016)

Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program
por: Yamada, Norikazu, et al.
Publicado: (2015)

Betrixaban for prevention of venous thromboembolism in acute medically ill patients
por: Beyer-Westendorf, Jan, et al.
Publicado: (2018)

Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
por: Bauersachs, Rupert, et al.
Publicado: (2020)

Treatment of Pulmonary Embolism With Rivaroxaban: Outcomes by Simplified Pulmonary Embolism Severity Index Score from a Post Hoc Analysis of the EINSTEIN PE Study
por: Fermann, Gregory J, et al.
Publicado: (2015)

Erratum to: ‘Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program’
por: Yamada, Norikazu, et al.
Publicado: (2016)

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018)

Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study
por: Willmann, Stefan, et al.
Publicado: (2018)

Rivaroxaban versus enoxaparin for the prevention of recurrent venous thromboembolism in patients with cancer: A meta-analysis
por: Xing, Jiali, et al.
Publicado: (2018)

Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies
por: Wang, Yuqi, et al.
Publicado: (2013)

Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist
por: Bamber, Luke, et al.
Publicado: (2015)

Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty: A meta-analysis
por: Huang, Hai-Feng, et al.
Publicado: (2018)

Cost-Effectiveness Rivaroxaban versus Enoxaparin for Prevention of Venous Thromboembolism after Knee Replacement Surgery in Iran
por: Abutorabi, Ali, et al.
Publicado: (2023)

Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice
por: Beyer-Westendorf, Jan, et al.
Publicado: (2017)

Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions
por: Willmann, Stefan, et al.
Publicado: (2021)

Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study
por: Kubitza, Dagmar, et al.
Publicado: (2018)

Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty
por: Levitan, Bennett, et al.
Publicado: (2014)

Comparison of Enoxaparin and Rivaroxaban in the Prophylaxis of Deep Venous Thrombosis in Arthroplasty
por: Çiçek, Necati, et al.
Publicado: (2021)

Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery
por: Huang, Qiang, et al.
Publicado: (2019)

Elastic compression stockings for prevention of the post-thrombotic syndrome in patients with and without residual vein thrombosis and/or popliteal valve reflux
por: Prandoni, Paolo, et al.
Publicado: (2021)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
por: Mueck, Wolfgang, et al.
Publicado: (2013)

Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial: Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial)
por: Longo de Oliveira, André Luiz Malavasi, et al.
Publicado: (2022)

The discovery of rivaroxaban: translating preclinical assessments into clinical practice
por: Kubitza, Dagmar, et al.
Publicado: (2013)

COSIMO – patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study
por: Cohen, Alexander T., et al.
Publicado: (2018)

Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registry
por: Müller, Stephanie, et al.
Publicado: (2022)

Prevention of venous thromboembolism with enoxaparin in bariatirc surgery
por: Woo, Hee Doo, et al.
Publicado: (2013)

Comparative analysis of enoxaparin versus rivaroxaban in the treatment of cancer associated venous thromboembolism: experience from a tertiary care cancer centre
por: Faqah, Anadil, et al.
Publicado: (2020)

Rivaroxaban and the EINSTEIN clinical trial programme
por: Cohen, Alexander T., et al.
Publicado: (2019)

Oral Rivaroxaban Versus Standard Therapy in Acute Venous Thromboembolism Treatment for Vietnamese Patients
por: Bui, My Hanh, et al.
Publicado: (2019)

Rivaroxaban for cancer-associated venous thromboembolism
por: Liang, Bo, et al.
Publicado: (2021)

Safety of Enoxaparin as Venous Thromboembolism Prophylaxis After Rhytidectomy
por: Lisiecki, Jeffrey L., et al.
Publicado: (2019)

Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis
por: Costa, Olivia S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_37n50ag8qvm1u8uuobv48i8suv